skip to Main Content

Licensing Agreement for Multiple Pediatric-focused Products between Lupin and MonoSol Rx

Reportedly, Lupin Pharmaceutical Inc.(LPI,US subsidiary of pharma major Lupin Limited) and MonoSol Rx, a specialty pharmaceutical company have entered into a strategic licensing agreement (OCT-2016) wherein Lupin would develop multiple pediatric products utilizing MonoSol Rx’s patented PharmFilm® drug delivery technology.

Lupin Limited is an innovation led transnational pharmaceutical company which develops and offers a wide range of branded & generic formulations, biotechnology products, and active pharmaceutical ingredients (API) globally. Lupin is the 5th and the 7th largest[1] generics pharmaceutical company by market capitalization and sales globally; the 3rd largest Indian pharmaceutical company[2] by revenues; the 6th largest generic pharmaceutical company in Japan and the 4th largest in South Africa.

Lupin Pharmaceuticals, Inc. Headquartered in Baltimore, Maryland, is dedicated to delivering high-quality, branded and generic formulations trusted by healthcare professionals and patients in the United States (US). LPI entered the US in 2004 and has since evolved into a market leader in generics and specialty pediatric treatments. LPI is the 5th largest pharmaceutical company in the US [3]by prescriptions.

MonoSol Rx is a specialty pharmaceutical company leveraging its proprietary PharmFilm® drug delivery technology in developing products that improve patient outcomes as well as address their unmet needs. These pharmaceutical and over-the-counter (OTC) products are developed independently and with partners. MonoSol Rx’s leadership in film drug delivery and is supported by strong IP protection, a robust pipeline of prescription drug formulations with two FDA-approved products – Suboxone® sublingual film and Zuplenz® oral soluble film.

Patients who may have difficulty swallowing pills or tolerating medication in traditional delivery forms, PharmFilm® technology basically provides a minimally invasive substitute to pills/injections/ gels, with the aim of helping patients adhere to their prescribed treatment regimens in order to improve their health, especially children. This technology specifically offers the potential to support pediatric patients in particular, having difficulty with the currently available oral or injectable dosing of required medications.

Lupin is known for its commitment and successful track record of improving accessibility, patient experience and addressing unmet medical needs globally. The agreement lies in line with the company’s focus; addressing urgent, unmet medical needs, expanding into the specialty pharmaceutical market- pediatric sector, by providing solutions to meet the needs of children for a variety of indications. PharmFilm provides a benefit to patients by improving the efficacy, safety, convenience and holds great promise for pediatric applications.

Hope to see more developed and valuable pediatric-focused products in future by Lupin.

About the Author: Dr.Komal Tomar, Sr. Licensing Associate at IIPRD and Khurana &Khurana, Advocates and IP Attorneys and can be reached at [email protected]

Back To Top